Collagen Solutions Share Discussion Threads

[gersemi] 03/9/2015 07:09

FDA approval

[doodlebug4] 01/9/2015 22:05

The chart I posted yesterday didn't load properly, let's see if this one works.


free stock charts from uk.advfn.com

[jacobjohn7] 01/9/2015 17:30

Yeah you're right db .... perfect company to be swallowed up potentially also...

[doodlebug4] 01/9/2015 08:59

I'm in for the long term as well jacobjohn, it's a share for the patient investor and not a share for thrills and spills! The chart is in a nice uptrend and the newsflow from the company is positive as well.

[jacobjohn7] 31/8/2015 19:57

All looking rosey for the future happy for long term hold from evidence im seeing and the market. . Dyor

[doodlebug4] 29/8/2015 16:20

Good coverage in the major Scottish newspapers.

[doodlebug4] 29/8/2015 08:58

Collagen Solutions wins Parkinson's Disease role.

The company said it will receive “significant funding” to develop various types of medical-grade collagens for investigation during the project, which is looking to progress treatments that are aimed at slowing the progression of the disease rather than just alleviating the symptoms.

The project is being led by CÚRAM, the Centre for Research in Medical Devices based at National University for Ireland in Galway, and is bringing together world-class researchers and industry partners to develop the first disease-modifying therapy for Parkinson’s, which could slow down its progression.

Stewart White, chief executive of Collagen Solutions, which rose from the ashes of Edinburgh life sciences firm Angel Biotechnology in December 2013, said being part of such a consortium was “further validation of the company’s reputation”.

“Our research and development capabilities, global reach, and state of the art manufacturing facilities in Scotland and New Zealand make us an obvious partner for this exciting project,” he said.

Collagen is a biomaterial found in body parts including skin and tendons, and Collagen Solutions’ products are currently used by its customers to develop medical products for applications including treating burns, grafting bones and tackling degenerative diseases.

Professor Abhay Pandit, director of CÚRAM, said: “Collagen Solutions’ ability to source, develop and manufacture collagen components for therapeutic use will be critical in meeting the requirements for a functional delivery formulation for the project.

“It is a mark of quality for all involved to have secured this grant funding, and we are very pleased to welcome Collagen Solutions to the consortium.”


Analyst Mike Mitchell, at house broker Panmure Gordon, said that, although there were relatively few details in the announcement around the specifics of Collagen Solutions’ role within the consortium, it was clear the company “will be exploiting its core competencies in the development and supply of medical grade products”.

“ParkinsonR17;s is a new disease area for the company but fits, in our view, with the company’s broad strategy to support therapies in areas such as regenerative medicine,” said Mitchell.

“Additionally, we consider this is an excellent example of how Collagen can deploy its expertise in material development to add to its pipeline of long-term product opportunities, embedding its technology at the early stages of research activity.”

Although the tie-up has not seen the broker change its valuation, Mitchell said he regarded it as “another example of Collagen’s ability to identify new fields of application for its materials technologies”.


The broker has a “buy” recommendation and 18p target price.

Last month Collagen Solutions said it was confident of building its valuation to £100m within the next five years – more than five times its current level – after seeing its annual sales soar.

The firm is also seeking to expand its manufacturing site in Glasgow to meet demand.

To help achieve its ambitions of becoming a global business, Collagen Solutions last year acquired New Zealand-based Southern Lights Biomaterials in a £6m cash and shares deal. Shares in Collagen closed up 0.5p, or 4.55 per cent, at 11.5p.

Scotsman.com

[doodlebug4] 28/8/2015 21:44

I missed this announcement in June:

Published Friday 26 June 2015 / Business



BIOMATERIALS manufacturer Collagen Solutions has appointed Panmure Gordon as its sole broker and nominated adviser (Nomad).

The company has also granted Panmure warrants to subscribe for more than 1.7 million new shares at a fixed price of 30 pence per share.

The warrants can be exercised at any point over the next three years.

Zeus Capital was the previous Nomad to the AIM-listed firm. Zeus and Panmure were also joint brokers to Collagen Solutions.

Herald Scotland

[doodlebug4] 28/8/2015 17:16

You said TERN was going back down to 2p a few months ago, remind me what the TERN share price is now- just one example. FOXT you said was going to be the best short of 2015 when the share price was 160p. Your list of disasters in 2015 is endless and you are the laughing stock of ADVFN.

[mike740] 28/8/2015 17:05

Tulip your wasting your money here. You know I know my stuff, even tho you dont like me personally.

Anyway im sorry to hear you have parkinsons. Genuine that. Hope this company can help you.

[mike740] 28/8/2015 14:33

Ayl30 your new bum boy Tulip?

pass this message onto him, if he as anything to say about me, to say it directly to me, not hiding in a group and holding your hand.

And if he wants we can always meet up and talk this through. As you know im always available for contact. Just ask him to pop over and see me and we can make arrangements.

[doodlebug4] 28/8/2015 14:22

Broker's target price was raised to 39p following the results published last month;

Collagen Solutions has created the bedrock to build out the business

13:13 15 Jul 2015
Research house Hardman has raised its target price for Collagen from 32p to an even more punchy 39p.

There is ample evidence that global device manufacturers want to work with Collagen Solutions
Collagen Solutions (LON:COS) is making significant progress towards its short term goals of cash flow break-even, research house Hardman says.

A note put out following full-year results on Monday from Collagen said evidence of cross-selling exists, with sales approaching £1mln for the developer and manufacturer of medical grade collagen components.

Revenue and other income for the year to the end of March 2015 rose to £1.04mln, and Hardman projects sales will rise to £3.7mln in the current financial year, reducing the underlying loss before interest, tax, depreciation and amortisation (LBITDA) from £726,000 in the year just gone to £273,000.

Hardman reckons it will be the year ending 31 March 2017 that will see the company move into profit, with EBITDA of £1.71mln on projected sales of £6.5mln.

“The combination of three businesses over the past 18 months has created the bedrock from which to build out the business. There is a customer base generating recurring revenues, a surety of supply of high grade collagen and the evidence that global medical device manufacturers want to work with COS [Collagen], evidenced by the four disclosed supply agreements announced over the past 12 months,” Hardman’s analysts say.

The integration of SLB appears to be well in hand, and the current year will see a full contribution from the recently acquired company.

The biggest danger to Hardman’s discounted cash flow-based valuation of 39p per share (up from 32p previously) remains the exact timing of development and manufacturing contracts and supply agreements, Hardman notes.

Shares in Collagen currently trade at around 10.5p.

[doodlebug4] 28/8/2015 14:04

Collagen Solutions joins fight against Parkinson's disease

07:38 28 Aug 2015
The company will be a key member of a team looking for a therapy that actually helps slow the growth of this debilitating and progressive illness.

Parkinson's is a disease of the central nervous system.
Collagen Solutions (LON:COL) has joined a landmark project that is aiming to develop novel new treatments of Parkinson’s disease.

The idea is to find a therapy that actually slows the progression of this debilitating illness rather than one that simply treats the symptoms.

The company will develop various types of medical-grade collagens for use in research.

As a key member of the team it will receive “significant funding”.

The project is being led by CÚRAM, the Centre for Research in Medical Devices based at the National University of Ireland, in Galway.

It has secured €4mln in funding through the European Horizon 2020 grant programme.

The project will bring together world class researchers from across Europe with businesses that can also help with the development of a treatment for Parkinson’s, a disease of the central nervous system.

Dr Stewart White, the chief executive of Collagen Solutions, said: "[We are] delighted to be part of such an esteemed consortium working on developing new therapies for such a devastating condition.

“I believe our shared success as part of the consortium provides further validation of the company's reputation for developing and suppling consistent high quality medical grade collagen products for its international clients.

“Our R&D capabilities, global reach, and state of the art manufacturing facilities in Scotland and New Zealand make us an obvious partner for this exciting project."

Proactiveinvestors.co.uk   

[mike740] 28/8/2015 13:28

Overated tosh.

[doodlebug4] 28/8/2015 13:23

More info about the project and the funding;

Objective

BrainMatTrain focuses on a comprehensive understanding of Parkinson’s disease (PD), from basics to translation, fully supported by 8 full partners partner organisation (4 research institutions, 2 hospitals, 2 SMEs) and one partner organisation (SME specialist in device design). This ETN will educate and train 15 Earlty Stage Researchers (ESRs) in functioanlised biomaterials, materials science, functionlisation strategies, molecular biology, stem cell biology, in vitro model systems, in vivo neuroimaging, animal models and prototype design. Recruited ESRs will receive compulsory discipline-specific, generic and complementary transferable skills training. BrainMatTrain will develop multi-modal collagen reservoir scaffolds incorporating moieties targetitng the neuroinflammatoiry and neuroprotective phases of the underlying pathology of Parkinson’s disease. The researchers will undertake cross-disciplinary and intersectorial research projects, which when married together will deliver a novel, biomaterial-based, therapeutic device for the treatment of Parkinson’s disease. The research training programme is designed to ensure high-calibre graduates, best placed to secure employment in the private or public sector. Fellows will experience both private and public sector research and development environments through a considered secondment plan.


Coordinator

NATIONAL UNIVERSITY OF IRELAND, GALWAYIreland
Participants

MEDIZINISCHE UNIVERSITAT INNSBRUCKAustria
EU contribution: EUR 255 934,08Austria
LUNDS UNIVERSITETSweden
EU contribution: EUR 527 318,64Sweden
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESFrance
EU contribution: EUR 525 751,2France
DANMARKS TEKNISKE UNIVERSITETDenmark
EU contribution: EUR 290 081,88Denmark
STICHTING KATHOLIEKE UNIVERSITEITNetherlands
EU contribution: EUR 255 374,28Netherlands
COLLAGEN SOLUTIONS (UK) LIMITEDUnited Kingdom
EU contribution: EUR 546 575,76United Kingdom
ORBSEN THERAPEUTICS LIMITEDIreland
EU contribution: EUR 265 674,6Ireland

[doodlebug4] 28/8/2015 08:41

RNS Number : 3589X

Collagen Solutions PLC

28 August 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Joins consortium developing new treatments for Parkinson's disease

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has been chosen to participate in a new research project to develop novel treatments for Parkinson's disease.

The project is being led by CÚRAM, the Centre for Research in Medical Devices based at NUI Galway, who have secured EUR4 million in funding through the European Horizon 2020 grant programme. The project, entitled 'Development of Biomaterial-based Delivery Systems for Parkinson's disease - an Integrated Pan-European Approach', facilitates collaboration between world class researchers and industry partners to develop the first disease-modifying therapy for Parkinson's, which could slow down the progression of the disease rather than offering mere symptomatic benefits

As a key member of the consortium, Collagen Solutions will receive significant funding to develop various types of medical grade collagens for investigation over the duration of the project.

Dr Stewart White, CEO of Collagen Solutions plc commented: "Collagen Solutions is delighted to be part of such an esteemed consortium working on developing new therapies for such a devastating condition. I believe our shared success as part of the consortium provides further validation of the Company's reputation for developing and suppling consistent high quality medical grade collagen products for its international clients. Our R&D capabilities, global reach, and state of the art manufacturing facilities in Scotland and New Zealand make us an obvious partner for this exciting project."

Professor Abhay Pandit, Director of CÚRAM, stated that: "CÚRAMs strength lies in establishing unique networks of synergistic national and international collaborations, integrating world class clinical, academic and industrial partners. Collagen Solutions' ability to source, develop and manufacture collagen components for therapeutic use will be critical in meeting the requirements for a functional delivery formulation for the project. It is a mark of quality for all involved to have secured this grant funding, and we are very pleased to welcome Collagen Solutions to the consortium."

[doodlebug4] 22/7/2015 08:45

RNS Number : 6896T

Collagen Solutions PLC

22 July 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Posting of Annual Report & Notice of AGM

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, confirms that the Annual Report and Accounts for the year ended 31 March 2015 ("2015 Annual Report and Accounts"), the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders on 29 July 2015.

The AGM is to be held at 10am on 24 August 2015 at the offices of Shepherd and Wedderbum LLP, 191 West George Street, Glasgow, G2 2LB.

A copy of the 2015 Annual Report and Accounts will be available from the 30 July 2015 on the Company's website: www.collagensolutions.co.uk

[jacobjohn7] 18/7/2015 09:10

Going it right direction plenty of positives in collagen solutions growing story ...

[doodlebug4] 15/7/2015 16:28

Research report now available on the Collagen website.

[doodlebug4] 15/7/2015 11:02

Collagen Solutions PLC Hardman & Co issues research on Collagen Solutions
Print
Alert
TIDMCOS

Collagen Solutions PLC

15 July 2015

Hardman & Co issues research report on Collagen Solutions

Embedding technology: gross margins will drive value Collagen Solutions (COS) reports on a year of change with significant progress being made towards its short term goals of cash flow breakeven. The acquisition of SLB is delivering on its strategic intent. Evidence of cross selling products and services exists with sales approaching GBP1m. With clear evidence of meaningful gross margins (78%) and new customer wins, the anticipated higher sales volumes should begin to offset the c. GBP1.5m central overhead with cash flow breakeven anticipated in H2 2015/16. These margins, in turn, are expected to drive long term shareholder value.

Please click here for the full report:

hxxp://www.hardmanandco.com/sites/default/files/research_papers/Collagen%20Solutions%20-%20FY%202015%20results_July%202015%20final.pdf


To contact us: Contact: Mark Brewer [e-mail]
Hardman & Co Martin Hall [e-mail]
11/12 Tokenhouse Telephone: [phone]
Yard Follow us on Twitter @HardmanandCo
London
EC2R 7AS

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

[mike740] 15/7/2015 10:08

ohhh Blueboy Lives in a dirty squat in Aberdeen, hes a night watchman who plays one share at a time (thats all he can afford), and used to send out his wife on the game until she got Arthritis in the back. Has a liking for young men.

COS not going anywhere other than down from here.